These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 31100584)

  • 1. In-silico analysis of Thr767Ile pathogenic variant in the MSH6 gene in family with endometrial cancer.
    Stembalska A; Klapecki J; Pławski A; Karpinski P
    Eur J Obstet Gynecol Reprod Biol; 2019 Jul; 238():54-57. PubMed ID: 31100584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation analysis of the MLH1, MSH2 and MSH6 genes in patients with double primary cancers of the colorectum and the endometrium: a population-based study in northern Sweden.
    Cederquist K; Emanuelsson M; Göransson I; Holinski-Feder E; Müller-Koch Y; Golovleva I; Grönberg H
    Int J Cancer; 2004 Apr; 109(3):370-6. PubMed ID: 14961575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rare germline mutation and MSH2-&MSH6 + expression in a double primary carcinoma of colorectal carcinoma and endometrial carcinoma: a case report.
    Zhang T; Huang X; Liu W; Ling X; Su Z; Huang M; Che S
    Diagn Pathol; 2024 Jan; 19(1):25. PubMed ID: 38297350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atypical HNPCC owing to MSH6 germline mutations: analysis of a large Dutch pedigree.
    Wagner A; Hendriks Y; Meijers-Heijboer EJ; de Leeuw WJ; Morreau H; Hofstra R; Tops C; Bik E; Bröcker-Vriends AH; van Der Meer C; Lindhout D; Vasen HF; Breuning MH; Cornelisse CJ; van Krimpen C; Niermeijer MF; Zwinderman AH; Wijnen J; Fodde R
    J Med Genet; 2001 May; 38(5):318-22. PubMed ID: 11333868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium.
    Plaschke J; Engel C; Krüger S; Holinski-Feder E; Pagenstecher C; Mangold E; Moeslein G; Schulmann K; Gebert J; von Knebel Doeberitz M; Rüschoff J; Loeffler M; Schackert HK
    J Clin Oncol; 2004 Nov; 22(22):4486-94. PubMed ID: 15483016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history.
    Kastrinos F; Steyerberg EW; Mercado R; Balmaña J; Holter S; Gallinger S; Siegmund KD; Church JM; Jenkins MA; Lindor NM; Thibodeau SN; Burbidge LA; Wenstrup RJ; Syngal S
    Gastroenterology; 2011 Jan; 140(1):73-81. PubMed ID: 20727894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a germline variant MSH6 c.4001G > C in a Lynch syndrome family.
    Yang C; Misyura M; Kane S; Rai V; Latham A; Zhang L
    Mol Genet Genomic Med; 2023 Feb; 11(2):e2104. PubMed ID: 36691871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of gene-specific germline pathogenic variants on presentation of endometrial cancer in Lynch syndrome.
    Bogani G; Ricci MT; Vitellaro M; Ditto A; Chiappa V; Raspagliesi F
    Int J Gynecol Cancer; 2019 May; 29(4):705-710. PubMed ID: 30772826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.
    Bonadona V; Bonaïti B; Olschwang S; Grandjouan S; Huiart L; Longy M; Guimbaud R; Buecher B; Bignon YJ; Caron O; Colas C; Noguès C; Lejeune-Dumoulin S; Olivier-Faivre L; Polycarpe-Osaer F; Nguyen TD; Desseigne F; Saurin JC; Berthet P; Leroux D; Duffour J; Manouvrier S; Frébourg T; Sobol H; Lasset C; Bonaïti-Pellié C;
    JAMA; 2011 Jun; 305(22):2304-10. PubMed ID: 21642682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-Occurrence of Familial Non-Medullary Thyroid Cancer (FNMTC) and Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Associated Tumors-A Cohort Study.
    Aswath K; Welch J; Gubbi S; Veeraraghavan P; Avadhanula S; Gara SK; Dikoglu E; Merino M; Raffeld M; Xi L; Kebebew E; Klubo-Gwiezdzinska J
    Front Endocrinol (Lausanne); 2021; 12():653401. PubMed ID: 34326811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant.
    Berends MJ; Wu Y; Sijmons RH; Mensink RG; van der Sluis T; Hordijk-Hos JM; de Vries EG; Hollema H; Karrenbeld A; Buys CH; van der Zee AG; Hofstra RM; Kleibeuker JH
    Am J Hum Genet; 2002 Jan; 70(1):26-37. PubMed ID: 11709755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of MSH6 gene mutation frequency in colorectal and endometrial cancers.
    Zhao YS; Hu FL; Wang F; Han B; Li DD; Li XW; Zhu S
    J Toxicol Environ Health A; 2009; 72(11-12):690-7. PubMed ID: 19492230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline truncating-mutations in BRCA1 and MSH6 in a patient with early onset endometrial cancer.
    Kast K; Neuhann TM; Görgens H; Becker K; Keller K; Klink B; Aust D; Distler W; Schröck E; Schackert HK
    BMC Cancer; 2012 Nov; 12():531. PubMed ID: 23164213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
    Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
    Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A mosaic pathogenic variant in MSH6 causes MSH6-deficient colorectal and endometrial cancer in a patient classified as suspected Lynch syndrome: a case report.
    Walker R; Clendenning M; Joo JE; Xue J; Mahmood K; Georgeson P; Como J; Joseland S; Preston SG; Chan JM; Jenkins MA; Rosty C; Macrae FA; Di Palma S; Campbell A; Winship IM; Buchanan DD
    Fam Cancer; 2023 Oct; 22(4):423-428. PubMed ID: 37318702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history.
    Buttin BM; Powell MA; Mutch DG; Babb SA; Huettner PC; Edmonston TB; Herzog TJ; Rader JS; Gibb RK; Whelan AJ; Goodfellow PJ
    Am J Hum Genet; 2004 Jun; 74(6):1262-9. PubMed ID: 15098177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome.
    Dillon JL; Gonzalez JL; DeMars L; Bloch KJ; Tafe LJ
    Hum Pathol; 2017 Dec; 70():121-128. PubMed ID: 29107668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lynch syndrome and Muir-Torre phenotype associated with a recurrent variant in the 3'UTR of the MSH6 gene.
    Cini G; Carnevali I; Sahnane N; Chiaravalli AM; Dell'Elice A; Maestro R; Pin E; Bestetti I; Radovic S; Armelao F; Viel A; Tibiletti MG
    Cancer Genet; 2021 Jun; 254-255():1-10. PubMed ID: 33516942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers.
    Goodfellow PJ; Buttin BM; Herzog TJ; Rader JS; Gibb RK; Swisher E; Look K; Walls KC; Fan MY; Mutch DG
    Proc Natl Acad Sci U S A; 2003 May; 100(10):5908-13. PubMed ID: 12732731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted Next-Generation Sequencing of
    Özdemir TR; Alan M; Sancı M; Koç A
    Balkan Med J; 2019 Jan; 36(1):37-42. PubMed ID: 30238922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.